International Journal of Molecular Sciences · 2020 · 16 citations · 29 references
MedicineNeurologyPharmacologyInflammationNeuroimmunologyNeuropharmacologyMultiple SclerosisMultiple Sclerosis PharmacotherapyNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationNeurological Disease ModelsExperimental Autoimmune EncephalomyelitisFingolimod TherapyIn Vivo Efficacy TestingMorpholine ChemistryMultiple Sclerosis ModelsMultiple Sclerosis TherapyRelapsing-remitting Multiple Sclerosis TreatmentSphingosine 1-Phosphate Receptor Modulator Therapy
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system (CNS) which is associated with lower life expectancy and disability. The experimental antigen-induced encephalomyelitis (EAE) in mice is a useful animal model of MS, which allows exploring the etiopathogenetic mechanisms and testing novel potential therapeutic drugs. A new therapeutic paradigm for the treatment of MS was introduced in 2010 through the sphingosine 1-phosphate (S1P) analogue fingolimod (FTY720, Gilenya®), which acts as a functional S1P1 antagonist on T lymphocytes to deplete these cells from the blood. In this study, we synthesized two novel structures, ST-1893 and ST-1894, which are derived from fingolimod and chemically feature a morpholine ring in the polar head group. These compounds showed a selective S1P1 activation profile and a sustained S1P1 internalization in cultures of S1P1-overexpressing Chinese hamster ovary (CHO)-K1 cells, consistent with a functional antagonism. In vivo, both compounds induced a profound lymphopenia in mice. Finally, these substances showed efficacy in the EAE model, where they reduced clinical symptoms of the disease, and, on the molecular level, they reduced the T-cell infiltration and several inflammatory mediators in the brain and spinal cord. In summary, these data suggest that S1P1-selective compounds may have an advantage over fingolimod and siponimod, not only in MS but also in other autoimmune diseases.
29
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Søren G. F. Rasmussen, Brian T. DeVree, Yaozhong Zou et al. · Nature · 2011 · 3.1K citations · Full text
Crystal Structure of a Lipid G Protein–Coupled Receptor
Michael A. Hanson, C. Roth, Euijung Jo et al. · Science · 2012 · 668 citations
Finding a way out: lymphocyte egress from lymphoid organs
Susan R. Schwab, Jason G. Cyster · Nature Immunology · 2007 · 591 citations
Visualization of arrestin recruitment by a G-protein-coupled receptor
Arun K. Shukla, Gerwin Westfield, Kunhong Xiao et al. · Nature · 2014 · 508 citations · Full text